2024
Risk of Infection in Older Adults With Type 2 Diabetes With Relaxed Glycemic Control.
Lipska K, Gilliam L, Lee C, Liu J, Liu V, Moffet H, Parker M, Zapata H, Karter A. Risk of Infection in Older Adults With Type 2 Diabetes With Relaxed Glycemic Control. Diabetes Care 2024 PMID: 39436715, DOI: 10.2337/dc24-1612.Peer-Reviewed Original ResearchRisk of hospitalizationIncreased risk of hospitalizationType 2 diabetesRelative riskIntegrated health care delivery systemGlycemic controlHealth care delivery systemCare delivery systemOlder patientsBone infectionIncreased riskRelative risk of hospitalizationEstimated incidence rateGlycemic control levelsRates of hospitalizationRetrospective cohort studySoft tissueCategories of infectionOlder adultsUnadjusted riskClinical guidelinesRisk of infectionIncidence rateCohort studyNegative binomial model
2023
Glycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: The Diabetes & Aging Study
Lipska K, Huang E, Liu J, Parker M, Laiteerapong N, Grant R, Moffet H, Karter A. Glycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: The Diabetes & Aging Study. Journal Of The American Geriatrics Society 2023, 71: 3692-3700. PMID: 37638777, PMCID: PMC10872822, DOI: 10.1111/jgs.18565.Peer-Reviewed Original ResearchConceptsRisk of complicationsComplication riskPoor healthIntermediate healthOlder adultsGood healthRetrospective cohort studyEndocrine Society guidelinesIntegrated healthcare delivery systemType 2 diabetesProportional hazards modelHealth status categoriesHealthcare delivery systemMacrovascular eventsCohort studyGlycemic controlPrimary outcomeSevere hypoglycemiaSociety guidelinesClinical variablesInsulin secretagoguesHazards modelComplicationsCombined outcomeAging Study
2021
882-P: QBSAFE: Pilot Study of an Intervention to Shift the Paradigm of Diabetes Care
CLARK J, BOEHMER K, BRESLIN M, HAIDER S, PASCIAK W, GRAVHOLT D, SANCHEZ B, HARTASANCHEZ S, EL KAWKGI O, MONTORI V, LIPSKA K. 882-P: QBSAFE: Pilot Study of an Intervention to Shift the Paradigm of Diabetes Care. Diabetes 2021, 70 DOI: 10.2337/db21-882-p.Peer-Reviewed Original ResearchDiabetes careSingle-arm pilot studyClinical encountersPilot studyMedication side effectsSubgroup of patientsBurden of treatmentFocus of careAddress patients' needsClinician-patient conversationsPost-visit surveysQuality of lifeRoutine clinical encountersHigh treatment costsUsual careGlycemic controlClinical visitsPatient participantsClinician participantsSide effectsPatientsPatient needsCliniciansTreatment costsQualitative semi-structured interviews
2019
1607-P: Prevalence and Correlates of Potential Glycemic Overtreatment and Undertreatment among U.S. Adults with Diabetes
MCCOY R, LIPSKA K, HOUTEN H, SHAH N. 1607-P: Prevalence and Correlates of Potential Glycemic Overtreatment and Undertreatment among U.S. Adults with Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-1607-p.Peer-Reviewed Original ResearchType 1 diabetesClinical complexityRace/ethnicityMale sexYounger ageAsian race/ethnicityHispanic race/ethnicityGlucose-lowering medicationsPoor glycemic controlLong-term complicationsHigh clinical complexityNational InstituteMedicare Advantage enrolleesAdministrative claims datasetEndocrine managementPatient comorbiditiesGlycemic controlTreatment regimenStudy cohortKidney diseasePotential overtreatmentDiabetesFM managementOvertreatmentU.S. adults
2018
Does Initiation of Basal Insulin Analogs in Patients with Type 2 Diabetes Mellitus Confer Advantages over Neutral Protamine Hagedorn (NPH) for Severe Hypoglycemia and Glycemic Control?
LIPSKA K, PARKER M, MOFFET H, HUANG E, KARTER A. Does Initiation of Basal Insulin Analogs in Patients with Type 2 Diabetes Mellitus Confer Advantages over Neutral Protamine Hagedorn (NPH) for Severe Hypoglycemia and Glycemic Control? Diabetes 2018, 67 DOI: 10.2337/db18-1311-p.Peer-Reviewed Original ResearchNeutral protamine HagedornType 2 diabetesReal-world clinical practiceSevere hypoglycemiaGlycemic controlInsulin analoguesClinical practiceKaiser Permanente Northern CaliforniaDiabetes medication useInsulin analogue useBasal insulin analoguesClinical trial populationsType of insulinHealth plan coverageHazard ratioInsulin initiationNPH insulinPatient characteristicsBasal insulinHemoglobin A1cMedication useSulfonylurea treatmentTrial populationHypoglycemic eventsNocturnal hypoglycemiaHigh-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions
MCCOY R, HOUTEN H, LIPSKA K, SHAH N. High-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1652-p.Peer-Reviewed Original ResearchEnd-stage renal diseaseChronic kidney diseaseChronic obstructive pulmonary diseaseMajority of patientsHeart failureMyocardial infarctionSerious comorbiditiesGlycemic controlCerebrovascular diseaseChronic conditionsHigh-risk medication usePlurality of patientsProportion of patientsObstructive pulmonary diseaseStage renal diseaseUse of insulinOptumLabs Data WarehouseTight glycemic controlHigh-risk drugsSerious chronic conditionsMedicare Advantage beneficiariesGlycemic targetsUrinary incontinenceMedication usePeripheral neuropathyCost-Related Insulin Underuse Is Common and Associated with Poor Glycemic Control
HERKERT D, VIJAYAKUMAR P, LUO J, SCHWARTZ J, RABIN T, DEFILIPPO E, LIPSKA K. Cost-Related Insulin Underuse Is Common and Associated with Poor Glycemic Control. Diabetes 2018, 67 DOI: 10.2337/db18-2-or.Peer-Reviewed Original ResearchCost-related underusePoor glycemic controlGlycemic controlDiabetes CenterCross-sectional surveyDM durationPrimary outcomeLess insulinHigher oddsPatientsSmall dosesDrug coverageLogistic regressionInsulinUnderuseMedicaid ServicesEssential medicinesNational InstituteInsulin 3Lower income levelsInsulin 5AgePositive responseHealthUrgent need